Asia Pacific Cell Culture Market Size, Growth, Share & Trends Analysis
Asia Pacific Cell Culture Market by Product [Consumable {Media, Sera, Reagent, Vessel (Roller Bottle, Flask, Cell Factory)}, Equipment {Bioreactor, Centrifuge, Filtration, Incubator}], Application [mAb, Vaccine, CGT], End User - Forecast to 2030
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The Asia Pacific cell culture Market, valued at US$6.49 billion in 2024, stood at US$6.98 billion in 2025 and is projected to advance at a resilient CAGR of 12.2% from 2025 to 2030, culminating in a forecasted valuation of US$12.40 billion by the end of the period. Biopharma companies in the region are expanding the production of monoclonal antibodies, vaccines, biosimilars, and recombinant proteins based on cell culture in the Asia Pacific cell culture market, which is thus growing. Besides, the demand from cell & gene therapy programs and translational research in big hospitals and university networks is rising. China, India, South Korea, Japan, Singapore, and Australia are experiencing considerable and fairly continuous inflows of capital into biomanufacturing capacity and CDMO infrastructures, making them consume more media, sera, reagents, and cultureware.
KEY TAKEAWAYS
-
By RegionThe Chinese cell culture market accounted for a 35.5% revenue share in 2024.
-
By ProductsBy product, the Asia Pacific cell culture market consumables segment is expected to register the highest growth.
-
By ApplicationBy application, the biopharmaceutical production segment is projected to grow at the fastest rate from 2025 to 2030.
-
By End userBy end user, the pharmaceutical & biotechnology companies segment is projected to grow at the fastest rate from 2025 to 2030.
-
Competitive LandscapeCompanies such as Thermo Fisher Scientific, and Danaher were identified as some of the key players in the Asia Pacific cell culture market, given their strong market share and product footprint.
-
Competitive LandscapeCompanies such as TransGen Biotech Co. Ltd. and HiMedia Laboratories have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The cell culture market in Asia Pacific is evolving into a high-growth space, supported by rapid expansion of biologics manufacturing, stronger vaccine and biosimilar pipelines, and rising investment in cell & gene therapy across both mature and emerging markets. Cell culture is a fundamental tool critical for bioprocessing and life science R&D in the region. It is the main source of upstream production for monoclonal antibodies, recombinant proteins, viral vectors, and new modalities. The growth is additionally driven by the expanding CDMO capacity, technology transfer projects, and the higher demand for media and reagents that are GMP-aligned and of a high-quality standard. Countries such as China, Japan, India, South Korea, Australia, together with the rest of the world are transforming clinical manufacturing and research ecosystems that require cell culture media, sera-free formulations, supplements, and cultureware as a continuous demand which is also increasing in these areas.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on stakeholders’ business in the Asia Pacific cell culture market is shaped by rapidly expanding healthcare and biomanufacturing infrastructure, strong government support for biologics and regenerative medicine, and rising patient demand for affordable, personalized care across diverse economies in the region. Hospitals and diagnostic laboratories, academic and government research institutes, and pharmaceutical and biotechnology companies across countries such as China, Japan, India, South Korea, and Australia are the primary adopters of cell culture solutions, as they scale monoclonal antibody and vaccine production, cell and gene therapy programs, translational research, and advanced in vitro disease modeling.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Rapid scale-up of biologics and vaccine manufacturing capacity
-
Growth in advanced therapies and tighter GMP expectations
Level
-
High qualification burden and variability in critical raw materials
Level
-
Serum-free and chemically defined media becoming the default
-
Closed, automated, and modular manufacturing sites
Level
-
Contamination control and lack of skilled biomanufacturing workforce
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Rapid scale-up of biologics and vaccine manufacturing capacity
The Asia Pacific is rapidly adding new biologics capacity. This directly lifts day-to-day demand for cell culture media, feeds, and supplements. Large CDMOs are expanding commercial bioreactor volumes across the region. For example, Samsung Biologics has been adding major capacity with its new plants coming online. WuXi Biologics is also expanding its network, including a large Singapore CRDMO hub. As more stainless-steel and single-use capacity get installed, media consumption becomes more recurring and predictable. This keeps the cell culture supply chain busy across China, South Korea, Japan, Singapore, India, and Australia.
Restraint: High qualification burden and variability in critical raw materials
Cell culture performance can change when raw materials shift a lot; even small variability can impact growth, yield, and product quality. That creates extra testing, comparability work, and change-control effort for manufacturers. The burden is higher when companies move toward complex, chemically defined formulations. It is also tougher when key inputs are sourced globally and require strong supplier oversight. Many Asia Pacific sites must balance quality expectations with cost and lead-time pressures. This slows switching and limits the rapid adoption of newer media systems in some plants.
Opportunity: Serum-free and chemically defined media becoming the default
Many Asia Pacific manufacturers want to reduce serum dependence. They want more consistent performance and fewer animal-derived risks. This is accelerating the adoption of serum-free and chemically defined media in both R&D and GMP settings. It opens room for premium media and feed packages. It also creates demand for media optimization support tied to specific cell lines and titers. Vendors that can prove robustness across lots win long contracts. Over time, this shift is expected to expand the value per liter of media sold in the region.
Challenge: Contamination control and lack of skilled biomanufacturing workforce
Contamination control is non-negotiable in cell culture, especially for advanced therapies. Regulators expect strong control strategies for media-related risks and supplier qualification. At the same time, many Asia Pacific employers report difficulty in finding skilled talent. This includes manufacturing and production skills that are critical for running cell culture operations. The result is higher training needs and more dependence on standardized workflows.
ASIA PACIFIC CELL CULTURE MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Sartorius built a GMP biologics facility for mammalian cell culture (CHO platform) to manufacture mAbs, recombinant proteins, and ADCs using single-use bioreactors as the backbone for scale-up. | Faster facility ramp-up | High flexibility for multi-product runs | No contamination reported | Shorter changeover cycles |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The Asia Pacific cell culture market ecosystem comprises suppliers of media, sera, reagents, and consumables such as Thermo Fisher Scientific, Cytiva, Merck KGaA, Fujifilm Irvine Scientific, Lonza, Corning, and multiple strong regional players, alongside providers of bioreactors, single-use systems, incubators, and other culture equipment. A growing base of contract development and manufacturing organizations (CDMOs), cell therapy manufacturers, and specialized cell culture service providers supports biopharmaceutical firms, clinical and research laboratories, and healthcare end users across countries including China, Japan, India, South Korea, and Australia, supplying solutions for biologics production, cell and gene therapy manufacturing, public-health and vaccine programs, and translational research across the Asia Pacific region.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Asia Pacific cell culture market, By Products
In 2024, consumables accounted for the largest share of the Asia Pacific cell culture market. Consumables?????? are the primary revenue source as labs and manufacturing sites continue to purchase media, feeds, supplements, serum-free/chemically defined formulations, reagents, and plasticware repeatedly. The demand is high in the six countries of China, Japan, India, South Korea, Singapore, and Australia, where the pipelines for biologics, vaccines and biosimilars are ??????expanding.
Asia Pacific cell culture market, By Application
In 2024, biopharmaceutical production noted the largest share of the Asia Pacific cell culture market due to the fact that cell culture is an important part of the processes that use cells to make monoclonal antibodies, recombinant proteins, vaccines, and biosimilars in the whole region. Big upstream processes call for large quantities of basal media, feeds, supplements, and single-use consumables; thus, the expense is recurring and easy to ??????forecast.
Asia Pacific cell culture market, By End user
In the Asia Pacific, pharmaceutical and biotechnology companies are the leading cell culture end users as of 2024. They?????? represented the largest share as cell culture is at the core of biologics and vaccine production, and these users purchase large quantities of media, feeds, supplements, and single-use consumables ??????regularly.
REGION
China to be the fastest-growing country in the Asia Pacific NGS market during the forecast period
The Asia Pacific cell culture market is expected to grow strongly over the forecast period, supported by significant investments in biomanufacturing, biosimilar development, and regenerative medicine across major economies in the region, with China emerging as the fastest-growing market. Large government-backed initiatives in China to expand biologics, vaccines, and cell and gene therapy capacity, combined with expanding CDMO infrastructure, strong local supplier presence, and rising clinical research activity, are rapidly increasing demand for advanced media, reagents, and single-use culture systems.
ASIA PACIFIC CELL CULTURE MARKET: COMPANY EVALUATION MATRIX
In the Asia Pacific cell culture market matrix, Thermo Fisher (Star) holds a leadership position due to its broad, end-to-end cell culture portfolio and strong regional reach. It is widely adopted for routine research culture and large-scale biopharmaceutical production, with a deep pull-through across media, serum-free/chemically defined formulations, supplements, reagents, and cultureware. FUJIFILM Holdings Corporation (Emerging Leader) is building visibility in Asia Pacific through a more specialized, high-value media focus, especially in advanced and sensitive workflows.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Thermo Fisher Scientific, Inc. (US)
- Danaher Corporation (US)
- Sartorius Inc. (US)
- Merck KGaA (Germany)
- HiMedia Laboratories (India)
- Fujifilm Holdings Coporation (Japan)
- Eppendorf SE (Germany)
- BD (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 6.49 Billion |
| Market Forecast in 2030 (Value) | USD 12.40 Billion |
| Growth Rate | CAGR of 12.2% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Countries Covered | China, Japan, India, South Korea, Australia, Rest of Asia Pacific |
WHAT IS IN IT FOR YOU: ASIA PACIFIC CELL CULTURE MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Global NGS platform & reagents manufacturer (Asia Pacific focus) |
|
|
RECENT DEVELOPMENTS
- October 2023 : Cytiva opened a manufacturing facility in Pune, India, which will double its manufacturing capacity in the country. This facility will produce bioprocessing equipment, including tangential flow, virus filtration, and inactivation systems, to support India’s growing biopharmaceutical industry.
- February 2023 : Eppendorf SE expanded its production operation in China with a new site in the Shanghai metropolitan region, manufacturing centrifuges locally to meet the rising demand. This strategic move improves customer proximity and reduces transportation emissions, aligning with Eppendorf’s sustainability goals.
- December 2022 : Thermo Fisher Scientific Inc. opened an 80,000 m² current good manufacturing practices (cGMP) facility in Hangzhou, China, which leverages single-use technologies in both drug substance and drug product manufacturing.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global Asia Pacific Cell Culture Market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the Asia Pacific Cell Culture Market. The secondary sources used for this study include World Health Organization (WHO), Food and Drug Administration, American Society for Cell Biology (ASCB), National Institutes of Health (NIH), International Society for Cell & Gene Therapy (ISCT), American Society for Gene and Cell Therapy (ASGCT), Centers of Disease Control and Prevention (CDC), International Serum Industry Association (ISIA), Pharmaceutical Research and Manufacturers of America (PhRMA), International Society for Vaccines (ISV), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the Society for In Vitro Biology (SIVB), Japan Agency for Medical Research and Development, European Federation of Pharmaceutical Industries and Associations (EFPIA), American Type Culture Collection (ATCC), and the Alliance for Regenerative Medicine (ARM); corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
After acquiring foundational knowledge about the global Asia Pacific Cell Culture Market through secondary research, extensive primary research was conducted. Multiple interviews were held with market experts from the demand side, including representatives from pharmaceutical and biopharmaceutical companies, hospitals & diagnostic laboratories, research & academic institutes, and CROs. Additionally, experts from the supply side were interviewed, including C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.
These interviews spanned five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while the remaining 30% were with demand-side participants. The primary data was collected through various methods, including questionnaires, emails, online surveys, personal interviews, and telephone interviews.
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the Asia Pacific Cell Culture Market. These methods were also used extensively to estimate the size of various subsegments in the market.
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Cell culture refers to removing cells from an animal or plant and their subsequent growth in an artificial environment under controlled conditions. It is a process of growing cells outside their natural environment, typically in a laboratory setting. This technique allows researchers to study cells in a controlled environment, providing insights into their behavior, growth, metabolism, and response to various stimuli.
Stakeholders
- Cell Culture Equipment and Reagents Manufacturers
- Analytical and Life Science Instrumentation Companies
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- Life Science Companies
- Venture Capitalists and Investors
- Government Organizations
- Private Research Firms
- Contract Research Organizations (CROs)
- Hospitals and Diagnostic Laboratories
- Cell Banks
Report Objectives
- To define, describe, and forecast the global Asia Pacific Cell Culture Market based on the product, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro-markets with respect to individual growth trends, future prospects, and contributions to the overall Asia Pacific Cell Culture Market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product launches, expansions, and R&D activities in the Asia Pacific Cell Culture Market
- To benchmark players within the Asia Pacific Cell Culture Market using the ‘Company Evaluation Matrix’ framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Asia Pacific Cell Culture Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Asia Pacific Cell Culture Market